Valeant Pharmaceuticals International Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (70)

Latest Posts

About This Stock More About This Stock
Week In Review: China's Creat To Restructure $1.5 Billion Biotest Takeover
Article By: ChinaBio® Today
Saturday, November 11, 2017 4:17 PM EST
Creat Group of China has withdrawn its current $1.5 billion offer to acquire Biotest, a German blood plasma products company, because US regulators refused to approve the deal, worried a China corporation would have access to US donor information.
In this article: VRX, CBMG
Investors Pummel Celgene
Article By: Shock Exchange
Friday, October 27, 2017 8:39 PM EST
CELG fell over 15% after Q3 earnings Thursday. Weak guidance, slowing growth from Revlimid and questions over the pipeline spooked investors.
In this article: CELG, VRX, JNJ
Concern Over Valeant's Financial Controls 'Likely Just Noise,' Says Cantor
Article By: The Fly
Friday, October 13, 2017 8:17 PM EST
Cantor Fitzgerald analyst Louise Chen says after speaking with the company, she believes the concerns are "likely just noise and cannot be strung together into an argument" that Valeant has issues with financial controls.
In this article: VRX Also: DEPO
Valeant Is Thirsty For New Capital
Article By: Shock Exchange
Monday, October 2, 2017 1:38 PM EST
VRX spooked investors last week when it filed an application to raise additional capital. Large asset impairment charges and/or legal exposures could erode the company's $4B capital base.
In this article: VRX Also: AGN, PSHZF
Valeant Attributes Today's Sell-Off To Confusion About Filing, Says Wells Fargo
Article By: The Fly
Thursday, September 28, 2017 5:47 PM EST
Valeant Pharmaceuticals suggested the 5% intraday pullback in its shares may be related to confusion about a recent regulatory filing concerning a potential offering, Wells Fargo analyst David Maris tells investors in a research note.
In this article: VRX


Latest Tweets for $VRX

No tweets yet!